ILCA 2021 - Annual Conference of the International Liver Cancer Association (Virtual Meeting)
Sep 02 - Sep 05, 2021 | BrusselsBelgium
LARVOL is not affiliated with Annual Conference of the International Liver Cancer Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 13 abstracts linked to Trials
[VIRTUAL] IDENTIFICATION OF REGORAFENIB PROGNOSTIC INDEX (REP INDEX) VIA RECURSIVE PARTITIONING ANALYSIS IN ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS RECEIVING SYSTEMIC TREATMENT
[VIRTUAL] Imbrave150: Albumin-Bilirubin (ALBI) Grade analyses in a phase III study of Atezolizumab (ATEZO) + Bevacizumab (BEV) versus Sorafenib (SOR) in patients (PTS) with unrespectable Hepatocellular Carcinoma (HCC)
[VIRTUAL] Nivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2
[VIRTUAL] Data from the third dose cohort and expansion phase of a Phase 1 trial of ADP-A2AFP SPEAR T-cells for patients with hepatocellular carcinoma and other cancer types expressing alpha-fetoprotein
[VIRTUAL] Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Updated interim analysis of the prospective observational REFINE trial
[VIRTUAL] A multicentred phase II clinical trial on serial combination of Yttrium 90-resin microspheres (Y90-RE) and chemotherapy for locally advanced intra-hepatic cholangiocarcinoma (ICC)
[VIRTUAL] A PHASE IB STUDY OF PEMBROLIZUMAB FOLLOWING TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN HEPATOCELLULAR CARCINOMA (HCC): PETAL.
[VIRTUAL] Characteristics of unresectable HCC patients in the new era of immunotherapy: first results from the ELITor study, based on the French prospective multicenter CHIEF cohort
[VIRTUAL] Mailed Outreach Strategy Significantly Increases Hepatocellular Carcinoma Surveillance Utilization: A Multi-Site Randomized Clinical Trial
[VIRTUAL] Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON
[VIRTUAL] REAL-WORLD OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH TRANSARTERIAL RADIOEMBOLIZATION: RESULTS FROM CIRT, A LARGE EUROPEAN PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY
[VIRTUAL] EXPLORATORY NETWORK META-ANALYSES OF SELECTIVE INTERNAL RADIATION THERAPY VERSUS SORAFENIB, LENVATINIB, AND ATEZOLIZUMAB-BEVACIZUMAB AS FIRST-LINE TREATMENT IN SUBGROUPS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA
[VIRTUAL] EFFECTIVENESS AND SAFETY OF LENVATINIB IN PATIENTS WITH RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION: RETROSPECTIVE ANALYSIS